{"prompt": "['considered as an event. TTP will be measured from the date of randomization to the date', 'of the first occurrence of BF, LF, RF, DM, of PCSM. Since TTP includes BF as a failure,', 'both definitions of BF will be used resulting in two TTP estimates.', 'Since baseline PSA level is not a stratification factor, hazard ratios and p-values for all', 'efficacy endpoints will be analyzed and reported after adjustment for baseline PSA.', 'Patients not experiencing an event will be censored at the last known follow-up time.', 'Competing-risk endpoints PCSM, LF, RF, TTP, and DM will treat death as a competing', 'risk (for PCSM and TTP, any death not due to prostate cancer) and be estimated by the', 'cumulative incidence method (Gray 1988). OS and FFBF will be estimated by the Kaplan-', 'Meier method (Kaplan & Meier 1958) and compared with the log-rank test (Mantel 1966).', 'Cox regression (1974) will be used to obtain hazard ratios (HRs) for OS and TTP. Fine and', \"Gray's regression (1999) will be used for the endpoints with competing risks. Adjusted\", 'HRs and the respective 95% confidence interval will be computed. Baseline PSA,', 'stratification variables (baseline EPIC score and ADT status), and, as appropriate, age,', 'race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical', 'power will be limited for these analyses.', 'Adverse Events', 'Adverse events (AEs) will be graded with CTCAE v4. Counts of all AEs by grade will be', 'provided by treatment arm. Counts and frequencies will be provided for the worst grade', 'AE experienced by the patient by treatment arm. A Chi-square test will be used to compare', 'the number of patients with at least 1 grade 3 or higher AE between the treatment arms. A', 'comparison of grade 3 and higher GU and GI events related to treatment (separately)', 'between treatment arms will also be tested using a Chi-square test.', '14.7', 'Exploratory Enppoints', '14.7.1 Exploratory Hypotheses and Endpoints', 'Measured utilities and cost-effectiveness for health outcomes using the EQ5D.', 'Paraffin-embedded tissue block, serum, plasma, whole blood, and urine for future', 'translational research analyses for predictors of toxicity following hypofractionated or', 'conventionally fractionated post-prostatectomy radiotherapy. Note: Testing of banked', 'specimens will not occur until an amendment to this treatment protocol (or separate', 'correlative science protocol) is reviewed and approved in accordance with National', 'Clinical Trials Network (NCTN) policies.', '14.7.2 Definitions of Exploratory Endpoints and How These Will Be Analyzed', 'Cost effectiveness', 'The VAS and index scores from the EQ-5D-5L will be calculated at each time point', '(baseline, end of RT, 6 months, and 1, 2, and 5 years from the start of RT) and compared', 'between treatment arms using a t-test with a 2-sided significance level of 0.05. If there', 'are significant differences, then a cost analysis will be conducted.', 'Quality-adjusted life years (QALY) is defined by the weighted sum of different time', 'episodes added up to a total quality-adjusted survival time. A Markov model will be used', 'NRG-GU003', '47', 'Version Date: April 26, 2019']['to model cost for this analysis. The Medicare reimbursement in dollars/QALY will be', 'calculated as a function of the monetary cost per relative value of each health state and its', 'duration. The EQ-5D-5L index score at 6 months and 5 years will be used for the cost-', 'utility analysis. The z-test will be used to test the hypothesis that the cost-utility in the', 'two treatment arms is the same with significance level of 0.05. The cost-utility using the', 'Medicare reimbursement in dollars/QALY between the two treatment arms after', 'adjusting for the baseline and stratification variables.', '14.8 Gender/Ethnicity/Race Distribution (26-APR-2019)', 'No differences across the patient subsets below are anticipated.', 'DOMESTIC PLANNED ENROLLMENT REPORT', 'Ethnic Categories', 'Racial Categories', 'Not Hispanic or', 'Latino', 'Hispanic or Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/Alaska', '0', '2', '0', '1', '3', 'Native', 'Asian', '0', '2', '0', '0', '2', 'Native Hawaiian or Other', '0', '1', '0', '1', '2', 'Pacific Islander', 'Black or African American', '0', '40', '0', '3', '43', 'White', '0', '139', '0', '10', '149', 'More Than One Race', '0', '1', '0', '1', '2', 'Total', '0', '185', '0', '16', '201', 'INTERNATIONAL (including Canadian participants)', 'PLANNED ENROLLMENT REPORT', 'Racial Categories', 'Ethnic Categories', 'Not Hispanic or', 'Hispanic or Latino', 'Latino', 'Total', 'Female', 'Male', 'Female', 'Male', 'American Indian/Alaska', '0', '0', '0', '0', '0', 'Native', 'Asian', '0', '1', '0', '0', '1', 'Native Hawaiian or Other', '0', '0', '0', '0', '0', 'Pacific Islander', 'Black or African American', '0', '2', '0', '0', '2', 'White', '0', '70', '0', '8', '78', 'More Than One Race', '0', '0', '0', '0', '0', 'Total', '0', '73', '0', '8', '81', 'NRG-GU003', '48', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}